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We recently identified a  protein,  designated  receptor 
accessory  factor (RAF), that interacts directly with and 
enhances the DNA binding of androgen ( A R )  and  glu- 
cocorticoid (GR) receptor peptide fragments. To de- 
termine its identity, RAF was  purified from HeLa cell 
extracts by anion-exchange  and DNA affinity  chroma- 
tography. RAF activity co-purified with a 110-kDa  pro- 
tein, the  partial  amino acid sequence of which  shares 
97.5% identity with insulin degrading  enzyme  (IDE),  a 
metalloendoprotease  implicated in the intracellular 
degradation of insulin. The identity of RAF was con- 
firmed in gel shift assays by  demonstrating  that A R e R A F  
and GR-RAF  DNA complexes shifted to a  slower  mobility 
in the presence of an IDE antibody.  Purified  prepara- 
tions of RAF had insulin degrading activity, and this 
activity  was inhibited by AR. In  addition, the interaction 
of AR or GR with RAF was competed by insulin and 
bacitracin,  a  competitive  inhibitor of IDE.  The interac- 
tions of AR and GR with IDE  may have important  impli- 
cations for  both insulin- and  steroid-mediated  signaling. 
Steroid  receptors are ligand-dependent  transcription  factors 
that bind steroid response elements within and adjacent to 
target genes (1-3). The mechanism  by  which  steroid  receptors 
regulate  transcriptional  activity is not  well  understood.  Several 
studies support the hypothesis that these receptors interact 
directly  with  other  transcription  factors  to  modulate  the initia- 
tion of transcription. In transient transfections  with  reporter 
genes,  DNA-binding  sites  for  various  transcriptional  activators 
cooperate  synergistically  with  steroid  response  elements to en- 
hance steroid-inducible transcription from heterologous pro- 
moters (4, 5). The glucocorticoid receptor (GR)’ interacts di- 
rectly  with  various  transcriptional  activators in  vitro, including 
c-Fos,  c-Jun, and octamer  transcription  factor I (6-9). Proges- 
terone and estrogen  receptors  interact  with  the general tran- 
scription  factor TFIIB, which is a component of the  preinitia- 
tion complex (10). These intermolecular  interactions  may  be 
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critical for mediating the transcriptional  activity of steroid  re- 
ceptors and for  conferring  steroid  hormone  specificity of gene 
expression. 
We recently  identified a protein,  designated  receptor  acces- 
sory factor (FUF), that directly interacts with and  enhances 
specific DNA binding of androgen  receptor (AR) and GR peptide 
fragments (11). Additional characterization of RAF revealed 
the following: 1) RAF interaction  with AR requires a region  in 
the AR NH,-terminal  domain; 2) RAF alone  does  not  bind an- 
drogen response element (ARE) DNA; 3) a survey of tissue 
culture  cell lines suggests that RAF is relatively ubiquitous; 
and 4 )  RAF has a predicted  molecular mass of 130 kDa by gel 
filtration. 
The  ability of RAF to  interact  with  and  enhance the DNA 
binding ofAR and GR suggested that RAF may be important  for 
transcriptional  activity of these receptors. To determine its iden- 
tity,  we  purified FUF from  HeLa  cell  extracts.  Amino  acid  se- 
quence  analysis  revealed  almost  complete  identity  with  insulin 
degrading  enzyme  (IDE), a metalloendoprotease  implicated  in 
the  intracellular  degradation of insulin.  Additional  studies con- 
firmed that RAF and IDE are  identical  proteins. The interac- 
tions  ofAR and GR with IDE may  have  important  consequences 
for  both  steroid- and insulin-mediated signal transduction. 
MATERIALS AND METHODS 
AR and GR Plasmids and Protein Expression-All plasmids were 
constructed as described  previously and contain DNA fragments ligated 
into PET-3 bacterial expression vectors  (11).  prAR(460-704),  prAR(460- 
6261, and prAR(521-704) containratAR DNAfragments encoding  amino 
acids 460-704,460426, and 521-704,  respectively. prGR(366630) con- 
tains  a rat GR DNA fragment encoding  amino acids 366-630. Each of 
these plasmids encodes a fusion protein that contains the  first 10 amino 
acids of  T7 gene 10 (12). These plasmids were used to transform 
BLal(DE3)pLysS cells, a strain of Escherichia coli carrying the gene  for 
T7 RNA polymerase. AR and GR peptide extracts were prepared and 
precipitated with ammonium sulfate, as described  previously  (11,131. Tu 
prepare a control extract for the insulin degradation assay, bacteria were 
transformed with the PET-3  vector lacking a DNA insert. For RAF pu- 
rification by DNA affinity chromatography, extracts of rAR(460-626) 
were purified further by phosphocellulose (P11) chromatography. 
Purification of RAF-”eLa-S3 cells (obtained from the National Cell 
Culture Center, Minneapolis, MN) were  grown in suspension in spinner 
flasks in Joklik’s minimum essential medium with 5% newborn calf 
serum. Cells were harvested at a density of 0.5 x lo6 celldm1 and 
washed  twice with phosphate-buffered saline. Cytosolic extract (S100 
fraction) was prepared from aliquots of 2.5 x lo9 cells based on the 
protocol by Dignam et al. (14). RAF was partially purified by anion- 
exchange chromatography using a 50-ml Q-Sepharose Fast Flow col- 
umn (Pharmacia LKB  Biotechnology Inc.). Cytosolic extract from  2.5 x 
lo9 cells (125 mg in a  total volume of 20 ml)  was chromatographed on 
the column,  which  was pre-equilibrated with  Buffer B (1 mM EDTA, 1 
mM dithiothreitol, 10%  glycerol, and 20 mM Tris, pH 8.0). Proteins were 
eluted with a gradient of 0-0.5 M KC1 and analyzed for RAF activity by 
the gel mobility shift assay, as described below. Fractions with RAF 
activity were desalted and concentrated, and then equilibrated in 
Buffer C (100 mM KCl, 0.1 mM EDTA, 1 ~ l l ~  dithiothreitol, 10%  glycerol, 
10 mM Tris, pH 7.5). 
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Thr  nrxt  purification strp utilizrd a DNA aflinity  column  conbining 
an  androgrn  respnnsc  elemrnt  (ARE) from the first intron of t h r   r a t  
prostntrin C3 grnr  (15).   Thr DNA aflinity  matrix was prrpnrrd hy t h r  
mrthod of Duncan  and  Cavnlirr ( 161  using a Trflon fihrr support drvrl- 
oprd as a suhstratr for olignnuclrotitlr synthrsis (Oligo-Affinity Sup- 
port.  Glrn  Rrsrarch.  Strrling. \'A). Thr  (::I oligonuclrotidr, 5'-ccagAG- 
T~~CCT(;ATT(;TTCTcnpggatcctatttn-3', \vas synthrsizrtl on a 1 pnml 
affinity matrix column using thr phosphnrnidr rnrthod (cnpitnlizrd 
nuclrotidrs rrprrsrnt thr AREI, and t h r  oligonuclc.otid~~, 5'-gatccct- 
~AGM<:ATCACCTACTctg~:~' ,  \\'as annralrd. as drscrihrd ll6I. Thr 
AliE affinity  matrix was insrrted  into30 mm x 2.0 mm ( innr rd iamrt r r )  
polyvinyl  chloridr  tuhing :and rquilihratrd  with  Ruffrr C. 
For  p r-adsorption of nonsprcific  protrins. thr  concrntratrd 
Q-Sqharosr  fraction 14.5 mg in a total volumr of3.0 mlj WIS chromato- 
graphrd on thr  ARE aflinity  column.  The  flow-through.  which  containrd 
lUl*'nctivity, was s:~vrd. and  hound  protrins.  which  did  not  contain  RAF 
activity. wrr r  rlutrd with Ruffrr C containing 1 KC1 and discardrd. 
T h r  flow-through \vas comhinrd  with 4.0 pg of phosphocrllulljsr-puri- 
fird rARt460426l  and 300 pg polyldl-tlCI in a total volumr of 3.0 ml 
antl  incuhatrd  fnr 15 min at .I 'C. Thr  protrin  mixturr was chromato- 
graphrtl on t h r  ARE  affinity  column  antl  wnshrd  with  Ruffrr C. Round 
protrins  wrrr rlutrd with hffrr  C containing 0.3 >I KCI. 
To prrparr  purifird I U F  for  analytical  studirs,  RAF  activity in ARE 
affinity  column  fractions \vas srpnratrd from AR hy prl filtration. ARE 
affinity  fractions 10.25 ml 1 wrrr  chrnmatogrnphrd on n 1 x 30 cm Su- 
prrosr 12 column  (Pharmacia LKR Biotrchnolop. Inc.1 rquilihratrd in 
I3uffrr D (0.55 \I KCI. 10'; glycrrol. 10 msr Tris. p I T  7.5) .  Fractions  wcrr 
drsnltrd and  concrntratrd.  antl  thrn  rquilihratrd in  Ruffrr I )  contain- 
inp 50 m\r KCI. Concrntratrd  fractions  wrrr  analyzrd fnr RAF activity, 
insulin  drgrading  activity,  and IDE immunoactivitv. :IS drscrihrd hrlow. 
All stagrs of RAF purification wrrr   prrfnrmrd  a t  4 'C. 
Amino Acid Sqrrrrtcr Arto/vsis-Fmctions with RAF activity from 
thr ARE affinity column wrr r  drsaltrd and concrntratrd. and thrn 
rquilihratrd in  I3uffrr C containing 50 my KCI. Proteins  wrre  srpnratrd 
hy 7.5'; sodium tlodrcyl sulfatc-polyncn.lamidr grl electrophoresis 
(SDS-I'./\GI.:I 17,. trnnsfrrrrd to an Immohilon-Pq' polyvinylidrnr di- 
fluoritlr(I'\'DF~  mrmhrnnr t Xlillipore Corp.. Rrdford, MA).  and  stainrd 
with 0.1'; Coomassir H l u r  in SOr; mrthanol. A uniqur 110-kDa  protrin 
hand 1 .:X0 pmol I  was rscised from thr membrane and suhmittrd to 
Iionald Nircr at the Univrrsity of \\'isconsin 13iotrchnology Crnter, 
Xladison for amino acid srqurncr  analysis hy autom:lted E t h a n  drg- 
rad:ation (Applird Riosytrms Pulsed-Liquid phasr scquencrr. modrl 
477AI. For  intrrnal  srquencr  analysis  PVDF-hound  protrin \vas cleavc.d 
with cyanogrn hromitlr. Prolinr rrsidurs wrrr idrntifird in various 
srqurncing  cvclrs,  and  uniqur  prptidrs  wrre  srqurncrd  aRrr  hlocking 
with  o-phthnlnldrhydr  (OPAI (181. 
Gr/ .\fnhi/it.v S/tif/ Assov-RAF activity was drtrctrd hy enhancr- 
mrnt  and rc*t;lrdation  ofAR.DNAand  C.R.DNAhindingcomplrxrs  in grl 
mohilitv shin assays. as tlrscrihrd  previously  (11 ). The oligonucleotide 
prohr  containrd :In ARE from thr  first  intron of thr rat  prostatein C:l 
grnr :  5'-cgaccngAGT~~('~TGAT(;~CTcagg-3' (15).  For  assaying RAF 
:tctivity during protrin purification. 2-3-pl aliquots of each fraction 
wrrr  comhinrd  with 10 ng of rARc46042(i)  rxtract. 0 3  pg of polytdl- 
dC), 100 pg of hovinr srrum  alhumin.  and  Ruffrr C containing 50 msr 
KC1 and incuhatrd for 15 min at 4 C. "I'-I,ahrlcd p r o h  10.2 ngI was 
;addrd. and snmplrs wrrr  incuhatrd for an  additional 30 min at 4 'C. 
I h i n e  insulin  or IDE inhihitors  tSigma)  wrrr addrd during  thr  prrin- 
cuhation strp to trst for thr i r  rffrcts on RAF activity. To analyzr for 
antihody rffvcts on protrin-I)NA complrxrs, various antihndirs were 
addrtl during the prrincuhation strp as indicatrd: 0.5 pg of the I g G  
fraction ofAIi52. a rahhit  polyclonal  antihody  raised  against n synthrtic 
prptidr rncompassing rat AR amino acids 525-541 1191; 0.5 pg of 
13LTGR2, n mousr monoclonal  antihody  rnisrd  against rat GR 120); and 
1-10 ng o f  9R12. a mousr monoclonal  antihndy  raisrd  ngninst  human 
IDE (kindly  providrd hy R. Roth,  Stanford)  (21). In somr experiments 
2-p1 aliquots of ARE aflinity column fractions, which containrd hoth 
rAR(460-626)  and  IUF,  wrrr usrd to t r s t  for insulin, IDE antihndy,  and 
II)E inhihitor  rffrcts.  Elrctrophorrsis  on sri nondrnaturing polyacryl- 
arnidr grls was prrformrd as drscrihcd  prrviously  (11 ). 
Inscrli~t Drgroclnlion Assoy-The prrcrntagr of insulin  degrading ac- 
tivity of purifird RAF snmplrs was  drterminrd hy a modific:ltion of t h r  
mrthod hy K u o  rl a / .  (221. Aliquots ( 2  pl) of pooled, cnncrntrated  frnc- 
tions from grl filtration-purifird RAF ( - 1  ng of RAF protrin) wrre 
incuhatrd  with 10 pmol of 3-I""'lliodotyrosyl A14 human  insulin (Am- 
ersham Corp.) for 30 min at 37 'C in  100 pI of Buffer E (50 SaCI. 2 
mw M & I 2 ,  50 p~ ZnCI,. 0.5 mR/ml bovine serum alhumin,  and 50 mst 
Na-HEPES, pH 7.51. Non-degraded  insulin was precipitated hy addition 
of 1 volume of 15'7 trichloroacetic  acid.  and  radioactivity  was  mcasurrd 
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Frc:. 1. Analysis of RAF activity  in Q-Sepharose and ARE affin- 
ity  fractions. RAF activity in (2-Srpharosr  fractions 1 / 1 * / ?  pcrttrll :Ind 
ARE affinity fractions iriglt! pond I was nnalyzrd hy motlility shift 
assay in .5'; nondrnaturing  polyacrylamide grls, Ench  hindinp  rraction 
containrd 10 ng of rARf460-6261  rstract, 0 . 2  ng of "P-lahrlrd CbARE 
oligonuclrotidr,  and 0.5 of polyidl-dC). Aliquots ( 2  1 1 1 1  of 5 ml of 
(2-Srphnrosr  fractions  or 0.2.5 ml ofARE affinity  fractions wrrr  addrd to 
thr  hinding  rractions.  Thr Iorm Inhrlrd I ,  contain  aliquots ( 2  pl1 of th r  
samplrs londrd onto  rach  column: l i t - l ,a  crll  rxtract for thr  Q-Srpharosr 
column  and  comhinrd  Q-Srpharosr frnction/rr\R~460-fi2fil for thc ARE 
affinity  column. Thc. mohility ofA1t.IUF.DSA :and ,\R.DSA comp1rsc.s 
arr indicatrd hy orrorrs. Sonsprcific complrsrs arr indicatrd I)?. t h r  
ostrrisl;. 
in a y-counter. As indicatrd,  insulin  drgrading  activity was analyzrd in 
thr   prrsrncr  of various IDE inhihitors  and  rat AR prptidrs. 
IDE I,r,mrrnocrrlir.il.v-Thr prrsrncr of IDE immunoactivity in gel 
filtration-purifird RAF snmplrs was drtermined hy imrnunohlotting 
with 91\12. an HIE monoclonal antihocly (211. IDE nntihody \vas 
drtectcd hy incuhation  with  horsrradish  peroxidasr-conjugntrd 
anti-mousr  antibody  and  rnhancrd  chrmiluminrscrnce  rragrnts 
( Amrrsham  Corp. I. 
RESULTS 
RAF Activit-v Co-purifies wi th  a  110-kDa  Protein-RAF was 
purified from HeLa  cells  because i t  is present  in  relatively  high 
concentration in these cells ( 11). C.ytosolic extracts of HeLa 
cells  contained  substantially  higher RAF activity  than  nuclear 
extracts; therefore, low salt extracts were utilized. RAF was 
monitored by its ability  to  enhance  the  binding  and  retard  the 
mobility  ofAR.DNAcomplexes  in gel mobility  shift  assays. RAF 
was partially purified on a Q-Sepharose anion-exchange col- 
umn;  RAF  activity  eluted at 0.3 51 KCI, as determined by en- 
hancement and shifting of AR.Dh'A complexes (Fig. 1, Ief! 
panel, fractions 8-9-11 ). In these assays the rat AR peptide, 
rAR(460-626),  was  expressed  in E. coli and  includes  the  DSA- 
binding  domain  and  short  segments of the NH,- and COOH- 
terminal  domains ( 11 ). The '"P-labeled oligonucleotide  probe 
contained a n  ARE from the first intron of the  rat  prostatein C.3 
gene ( 15). 
The  next  step of purification was based on the observation 
that  RAF  binds ARE-DNA only  in  the  presence of  AR 11 ). The 
Q-Sepharose fractions with RAF activity were desalted, con- 
centrated,  combined  with  rAR(460-626).  and  chromatographed 
on a n  ARE-DNA affinity column. Fractions containing RAF 
activity  eluted at 0.3 51 KC1 (Fig. 1, right panel,  fractions .?-5) 
and  revealed a specific pattern of protein  bands by SDS-PAGE 
(Fig.  2, Q+AR, lane 4 ). If,  however, Q-Sepharose  fractions  were 
chromatographed on the ARE affinity  column  in  the absence of 
AR, the  high  salt  elution  did  not  contain  RAF  activity  (data  not 
shown ). Analysis of these  fractions by SDS-PAGE revealed the 
same  pattern of protein  bands  except  for  the  absence of a 110- 
kDa  protein (Fig. 2,  compare Q ,  lane 2 and Q+AR. lane 4 ). No 
eluted  proteins  were  observed  after  chromatography of 
rAR(460-626)  alone  on  the ARE affinity  column (lane 3 ). The 
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FIG. 2. RAF activity co-purifies with a 110-kDa protein. 
Q-Sepharose  fraction  alone (Q, lnnr 21, rAR(460-6261 alone ( A R ,  lane 
3 I,  or a  comhination of Q-Sepharose  fraction  and rAR(460-626~ (Q+AR, 
lane 4 )  were  chromatographed on the ARE affinity  column.  Proteins  in 
each sample were elutrd  with 0.3 $1 KC1 and analyzed hy 7.!jri SDS- 
PAGE and  silver  staining.  In lane I (Q'+AR ) the  concentrated  Q-Sepha- 
rose fraction  was  first  chromatographed on the ARE affnity column  in 
the  absence of AR to prr-adsorh nonspecific proteins.  The  flow-through 
was comhined with AR and  re-chromatographed on the ARE affnity 
column after washing the column with 1 51 KC1 and re-equilibrating 
with Buffer C (see  'Materials  and Methods"). The arrow indicates  the 
uniqur 110-kDa protein  present  in th r  Q+AR samples  compared  with 
either  the Q or AR samples  alone. 
20-kDa AR peptide was  not resolved on a 7.5% polyacrylamide 
gel. A  more  purified RAF protein sample  was  obtained  when  the 
Q-Sepharose fractions were first chromatographed on the ARE 
affinity column in the  absence of AR to pre-adsorb nonspecifi- 
cally bound proteins. The flow-through was combined with AR 
and re-chromatographed  on the DNA affinity  column. Recovery 
of RAF activity  corresponded with  the  appearance of the 110- 
kDa protein (Fig. 2, lane 1). We attempted to recover RAF 
activity from SDS-PAGE gels by extracting  and  renaturing  the 
110-kDa protein, as  well as  other  proteins  bands; however, RAF 
activity was  not  detected. 
RAF Amino Acid Sequence Is Homologous to Insulin  Degrad- 
ing Enzyme-Based on the observation that RAF activity co- 
purified with a 110-kDa protein,  samples of this protein were 
submitted for amino acid  sequence analysis by automated  Ed- 
man degradation after transfer to a PVDF membrane. Our 
failure to obtain sequence suggested that  the NH, terminus 
was blocked. The protein was  therefore cleaved with cyanogen 
bromide and blocked with OPA a t  proline cycles for internal 
sequence analysis. Amino acid sequence  was  obtained from two 
peptides yielding  a total of 40  residues. Comparison with  the 
GCG data  base revealed 97.5% identity with IDE, a metalloen- 
doprotease that degrades insulin in uitro and is believed to 
have a  role in  intracellular  insulin  degradation (23). 
Purified RAF Has Insulin Degrading Actiuit-y and IDE 
Immunoactiuity-To determine whether RAF and IDE were 
identical,  RAF-containing ARE afinity column fractions were 
purified further  and  separated from AR by gel filtration  in high 
salt. Gel filtration  fractions were analyzed for RAF activity by 
gel shift  assay in the presence of AR (Fig.  3R),  as described 
above. Fractions were also  assayed for insulin  degrading activ- 
ity by measuring  the  percentage of trichloroacetic-soluble 
counts after incubation with "'1-insulin (Fig. X ) .  RAF and 
insulin  degrading  activities co-eluted. In addition, an immuno- 
blot of these  fractions  using  an IDE monoclonal antibody,  9B12 
(21). revealed that RAF and insulin degrading activities co- 
eluted with immunogenic IDE (Fig. 3A). These observations 
suggested that RAF and IDE are identical  proteins. However, 
the possibility that IDE was a  co-migrating contaminant of the 
RAF fractions was  not excluded. 
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FIG. 3. Purified RAF has insulin degrading activity and IDE 
immunoactivity. RAF-containing ARE affinity fractions were ana- 
lyzed by gel filtration on a  Superose 12 column equilihrated  in Buffer D 
with 0.55 31 KC1 (see  "Materials  and  lfethods"). Gel filtration  fractions 
were analyzed for: A, IDE immunoactivity by immunoblotting with 
9B12, a  human IDE monoclonal antibody; R, RAF activity by gel mo- 
bility shift assay. as described in  the legend to Fig. l;  and C,  insulin 
degrading  activity hy measuring  the  percentage of  trichloroacetic acid- 
soluble  counts  after  incubation  with '"I-insulin for 30 min at  37 'C. 
IDE Antibod-v Retards  the Mobility of AR.RAF and GR.RAF 
DNA  Complexes-To confirm that RAF and IDE are  the  same 
proteins, gel mobility shift assays were performed using the 
IDE antibody, 9B12. The typical AR.RAF.DNA complex is 
shown in  lane 5 (Fig. 4A ). Addition of increasing concentrations 
of IDE antibody shifted the AR.RAF.DNA complex to more 
slowly migrating complexes (lanes 6-8). The effect of IDE an- 
tibody on the formation of GR.RAF complexes was analyzed 
using a rat  GR peptide,  rGRf366-630), that  includes  the DNA- 
binding domain and flanking sequences. The GR.RAF.DNA 
complex (Fig. 4B, lane 5) was also shifted to more slowly mi- 
grating complexes in  the presence of IDE antibody (lanes 6 - 8 ) .  
The IDE  antibody produced no additional or shifted bands  in 
the presence of AR or GR alone (Fig. 4, A and B,  lanes 2 4 )  or 
with RAF alone  (data not  shown). These  results indicated that 
RAF and  IDE  are identical proteins. 
Insulin  Inhibits RAF Interaction with AR and   GRSince   i t  
appeared  that  an AR peptide fragment could bind IDE, a pro- 
tein  that  binds  insulin in uitro, we  h-ypothesized that  the IDE- 
binding  sites for AR and  insulin may be identical. To test  this 
possibility, RAF activity with rAR(460-626) was analyzed in 
the presence of insulin.  The formation of the AR.RAF complex 
(Fig. 5 4 ,  lane 1) was  inhibited by increasing concentrations of 
insulin  (lanes 2-5 ). In contrast, AR-DNA binding was enhanced 
with increasing  insulin  concentrations  (Fig. 5A,  lanes 2-5) sug- 
gesting that AR is displaced from RAF by insulin. An AR.AR 
antibody complex (lane 6) was used as  a control to test for a 
generalized effect of insulin on the formation of an AR hetero- 
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FIG. 4. IDE antibody retards the mi- 
complexes.A. l l ~ ~  c.ffvct ofthr 9H12 l l ) K  
AII.lL\F.I)NA complexes was tested hy 
rnonor1on:ll antihody on thr migration nf 
grl shift assay using  ."P-lahrlrd  (3-ARE 
prohr. Imnrs 1 4  IAR) contained 10 ng 
rAH1460-626)  extract. Imnrs .i4 (AN+ 
I U F l  containrd 2-111 aliquots of ARE af- 
finity fmctions contnining rARc46O-626) 
and RAP. Imnrs 2 4  and lnnrs 6-8 con- 
tainrtl 1, 4, and 10 ng of I D F :  antihody 
( I I IE  Ah ), resprctivrly. E .  thr  r lrrct  of IIIE 
antihotly on thr migration of GR.RAI*'. 
I)SA complrxrs was t rs t rd  hv grl shift 
assnv, as ahow. IAws 1-1 I GR ) contninrd 
~ G K + I ~ A F I  contained 1 pg of tCR(366- 
1 pg of rGRf.166-690) rxtract. Imnrs 5 - 8  
6301 rxtract  and 1 ng of grl filtration-pu- 
rifird IWF. Thr quantit irs of IDE anti- 
hotly wrrr the  same as ahove. 
AR 
AR + RAF AR Ab + 
" 
insulin (uM) - .01 0.1 1.0 10 - 10 
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GR + RAF GR Ab + 
" 
insulin  (uM) - .01 0.1 1.0 10 - 10 
QR-QR Ab * . .  
OR t 
AR-FtAF and GR.RAF.DNA complex- 
FIG. 5. Insulin  inhibits  formation of 
es. A ,  the rflict of insulin on hR.IL\F. 
DNAcomplexes was trstrd hygel  mohility 
shift assay. Imnes 1-i lAR+RAFI ron- 
tained 2-pl aliquots of ARE affinity col- 
umn fractions containing rARl460-626) 
and RAF. Imnes 6 and 7 (AH+AR A h )  
contained 10 ng of rAR1460-6261 extract 
and 0.5 pg of AR52. an A K  antihocly  In- 
sulin was added  to  the  hinding  reactions 
at the indicated final concrntrations. B, 
the  effect of insulin  on  GR.RAF.Dh'A 
complrxes \vas tested hy grl rnohility 
shift assay. IAncs 1-5 tGR+RAFl con- 
tained 1.0 pg of rGR(366-6.70, extract 
and 1 ng of gel filtration-purified RAP. 
I ~ n e s  6 and i (GR+GR A h )  contained 1.0 
pg of K,I~~."X-m~ rxtract  and 10 ng of 
I3UGR-2, a CR antihody.  Insulin was 
nddrd to the  hinding  reactions at the  in- 
dicated  final  concentrations. 
1 2 3 4 5 6 7  
1 2 3 4 5 6 7  
meric complex. The AR antibody  was a peptide-generated  rab- 
bit polyclonal antibody, AR52 (19). Formation of the AR.AR 
antibody  complex  was  not  inhibited by 10 p~ insulin  (lane 7).  
The  effect of insulin  on  the  formation of CR-RAF  complexes 
was also analyzed using rGR(366-630). Insulin  inhibited  the 
formation of GR.RAF  complexes  (Fig. Til?, compare lanes 1 and 
2-5 ), whereas  insulin  had  no  effect  on  GR.GR  antibody  complex 
formation (compare Ianm f i  and 7). The CR antibody was a 
mouse  monoclonal  antibody, RUGR-2 (20).  Thus,  insulin com- 
petes  with AR and  GR for hinding  to RAF, providing  further 
evidence tha t  RAF  and IDE are  identical  proteins. 
AR Inhihits  Insulin DegradingActiL1it.v of W - T h e  compe- 
tition of insulin  and AR for hinding  to  RAF  suggested  that AR 
might  inhibit  insulin  degrading  activity of RAF. To test this 
hypothesis,  insulin  degrading  activity of purified  RAF  prepa- 
rations was measured  in  the  presence of various AR peptides 
expressed  in E. coli (Fig. 6.4). rAR(460-704)  inhibited  insulin 
degrading  activity of RAF by 35% at  the  maximum  concentra- 
tion of extract  tested  (Fig. 6R ), whereas a control  bacterial ex- 
tract   that  did  not  contain AR enhanced  insulin  degrading  ac- 
tivity of RAF hy 14%.  In  contrast, rAR(521-704), a n  AR peptide 
that  does  not  interact  with RAF due  to  deletion of NH,-terminal 
amino  acids 460-520 (11 1, did  not  inhibit  insulin  degrading  ac- 
tivity. rAR(460-626),  which  does  interact  with RAF, caused 70T 
inhibition of insulin  degrading  activity.  The  greater  insulin  de- 
grading  activity  inhibition of rAR(460-626)  than  rAR(460-704) 
correlates  with a 2-3-fold higher level ofexpression of  rAR(46O- 
626), as observed by "'S-labeling of bacterial  cultures  (data  not 
shown).  Given  that AR peptides  hind RAF  directly, these  data 
suggest  that AR can block insulin  degrading  activity of RAF by 
competing  for  insulin  binding.  These  results  also  provide  addi- 
tional  evidence  that  RAF  and IDE are the  same  proteins. 
Effects of IDE  Inhibitors on RAF Acfiuit-v-The insulin  de- 
grading  activity of IDE is inhibited  by a number of substances, 
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FIG. 6. AR inhibits insulin degrading activity of RAF. A, sche- 
matic of full-lenflh  rat AI{ (rAR) and AI< peptides  expressed  in E. coli, 
as  described  untlrr  "\laterials  and  \lethods." Shnrfrd nrens indicate  the 
DNA-binding domain,  and hn/rhrd nrrns indicate  the  steroid-hinding 
domain. R .  effect ofAR peptides on insulin  degrading  activity of purified 
RAF. Gel filtration-purifird ltAF I 1  ng1 was  lncuhated  with 10 pmol of 
'"''I-insulin for 30 min at 37 C. Various concentrations of AR peptide 
extracts were added to the insulin demading reactions, as  indicated. 
The control extract  was  prepared from an E. roli clone transformed  with 
a PET-3 expression vector lacking insert DNA. Son-degraded insulin 
was precipitated with 1.5% trichloroacetic acid. and radioactivity WRS 
measured in a y-counter. Each data point  represents  the  mean f S.D. of 
three  assays. 
including  sulfhydryl  agents,  such as N-ethylmaleimide (NEM) 
and p-hydroxymercurohenzoate (HMRA),  and  competitive  in- 
hibitors  such as bacitracin (24-26). NEM  and HMRA inhibit 
insulin  degrading  activity of IDE by interfering  with its cata- 
lytic activity, however, they do not inhibit insulin binding to 
IDE.  In  contrast,  bacitracin  inhibits  both  insulin  binding  and 
catal-ytic activity.  The  effects of these  IDE  inhibitors  on RAF 
activity  were  analyzed  and  compared  with  their  effects  on  in- 
sulin  degrading  activity of RAF. Although  increasing  concen- 
trations of NEM  and HMRA inhibited  insulin  degrading  activ- 
ity of purified RAF, these  IDE  inhibitors  did  not  interfere  with 
the  ability of RAF  to  bind  rAR(460-626) (Fig. 7, A and R). In 
contrast,  bacitracin  inhihited  both  insulin  degrading  and RAF 
activities (Fig. 7C), consistent with its property as an IDE 
competitive  inhibitor.  Formation  ofAR.AR  antibody  complexes 
was unaffected by NEM, HMRA, or bacitracin (Fig. 7, A-C). 
These  experiments  suggest  that  the  interaction ofAR with  IDE 
does  not  depend  on  the  catabytic  activity of IDE. 
DISCUSSION 
Our  studies  indicate  that RAF, a factor  that  interacts  with 
and  enhances  the DNA binding ofAR and GR peptides in uitro, 
is IDE. RAF activity co-purified with a 110-kDa protein, the 
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FIG. 7. Effects of IDE inhibitors on RAF activity and insulin 
degrading activity. G r l  mohility shift  assays (rig/?/ pnnels I were per- 
formed as tlescrihed in the legend of Fig. 1. AR+RAF samples  contained 
2-pl aliquots of ARE aninity fractions containing rARI460-6261 and 
RAF. AH+Ali Ah samples  contained 10 ng of rAR( 460-626 I and 0.5 pg of 
AI1 antihody. Insulin  degrading assays ( k f ?  panels I were performed as 
drscrihed in the legend of Fig. 6. SEX1 fA J, HXIRA ( R  ). and bacitracin 
( C  I were  added to IISA binding  and  insulin  degradation  assays at  the 
indicated  concentrations. Each data point represents  the  mean z S.D. of 
three  assays. 
with  IDE.  The  identity of RAF was  confirmed  in gel shift  assays 
by demonstrating  that AR.RAF and GRsRAF DNA complexes 
shifted  to a slower  mobility  in the  presence of a n  IDE mono- 
AR and GB interact with IDE 20627 
clonal antibody. Furthermore, purified preparations of RAF' 
had  insulin degrading activity, and  this activity was inhibited 
by AR. In addition, RAF activity was competed by insulin, as 
well as by bacitracin, a competitive inhibitor of IDE. These 
results  support our conclusion that RAF and IDE are identical 
proteins. 
In our experiments to date, we have demonstrated RAF ac- 
tivity with E. coli-expressed AR and GR peptide fragments. We 
originally reported that partially purified RAF mediates en- 
hancement of  DNA binding of baculovirus-expressed, full- 
length human GR (11). However, this activity did not co-elute 
with RAF protein when it was subsequently purified to near 
homogeneity. RAF enhancement of DNA binding of baculovi- 
rus-expressed full-length AR or GR has not been  observed in 
mobility shift assays. Possible explanations for this discrep- 
ancy may be that baculovirus-expressed receptors are not in 
the proper conformation  for interaction with IDE or that  an 
additional proteinis) is required for their interaction. Func- 
tional studies are currently  in progress to identify an in vivo 
interaction between IDE and AR or GR. 
IDE is a neutral thiol me~loendoprotease  that degrades 
insulin  in vitro (23). Purification schemes for  IDE utilized the 
cytosolic fraction (24, 26); however, the  ~stribution of the en- 
zyme in intact cells is unknown. The purified enzyme has a 
molecular mass of 110 kDa and has  an affmity for insulin of Kd 
= 100 IIM (26). The human IDE cDNA has been  cloned, and the 
predicted protein has  a calculated molecular mass of 110 kDa 
(27). IDE transcripts are ubiquitously expressed and develop- 
mentally regulated in  rat issues, with highest concentration in 
mature  testis (28-30). 
The catalytic and insulin-binding sites of IDE appear to  be 
distinct. Mutation of a putative zinc-binding domain in IDE 
eliminates catalytic activity but not insulin binding (31, 32). 
Non-competitive inhibitors of IDE's catalytic activity, such as 
NEM and HMBA (24, 251, do not block the binding of either 
insulin or AR to IDE, Furthermore, bacitracin, a competitive 
inhibitor of IDE, blocks both insulin  and AR binding. These 
data and the competition of AR and  insulin for  IDE binding in 
uitro implies that their IDE-binding sites are identical, or at 
least overlapping. 
IDE is implicated in having a physiological role in intracel- 
lular  insulin degradation based on several lines of evidence. 
For example, inh ib i~rs  of purified IDE in vitro inhibit  insulin 
degradation in vivo (25, 33). Additionally, the microinjection of 
IDE  monoclonal antibodies inhibits  intracellular  insulin deg- 
radation (21). Furthermore, expression of the IDE cDNA in 
various cultured cell lines results  in increased insulin degrad- 
ing activity in cell extracts  and in whole  cell assays (22). If IDE 
mediates degradation of intracellular  insulin in vivo, IDE may 
have a role in regulating insulin action by terminating the 
insulin signal. 
The interaction of IDE with AR and GR in uitro invokes 
several hypotheses relating to its potential impact on insulin 
and steroid signaling. First, these steroid receptors may be 
substrates for XDE proteolysis. This possibility is not unprece- 
dented because, in addition to insulin, IDE degrades other pro- 
teins in vitro, including transforming growth factor a! (34), 
atrial  natriuretic factor (35), and insulin-like growth factors I 
and TI (36). If  IDE degrades AR and GR in uivo, IDE may have 
a role in regulating steroid action by modulating steroid recep- 
tor concentrations. Second, Aft and GR may interact with IDE 
to regulate its insulin degrading activity. Such a relationship 
could have important pathophysiolo~c implications for insulin- 
resistant conditions associated with gluc~orticoid or androgen 
excess. Third, IDE  may directly modulate the transcriptional 
activity of these steroid receptors. The hetero~me~zat ion of 
retinoid X receptors with the retinoic acid-vitamin D-thyroid 
hormone receptor subclass of nuclear receptors results in en- 
hancement of  DNA binding and  transcriptional activity and  in 
some cases determines DNA binding specificity (37, 38). The 
interaction of GR with the AP-1 transcription factor may re- 
press or activate  transcriptional activity of GR depending on 
the promoter context or the combination of Fos and Jun family 
members in the complex (39-41). Likewise, interaction of IDE 
with AR or GR could  specify unique DNA-binding sites for these 
receptors in steroid-regulated genes, resulting in either  tran- 
scriptional activation or repression. 
Cross-talk between signal transduction pathways increas- 
ingly has been recognized as a common paradigm in cellular 
development and homeostasis.  IDE has been  hypothesized to 
play a role in  the intracellular degradation of insulin andor 
other peptide hormones. The interaction of IDE with AR and 
GR potentially couples insulin  and steroid hormone signaling 
pathways. This relationship may be important for various bio- 
logical phenomena, such as insulin resistance, steroid receptor 
metabolism, or specificity of steroid hormone action. 
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